Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Helicobacter pylori
New findings in helicobacter pylori described from University of Melbourne
September 3rd, 2008
"An important obstacle to development of an effective vaccine against Helicobacter pylori is the lack of a suitable adjuvant. This study evaluated the effectiveness of ISCOMATRIX (TM) and ISCOM (TM) vaccines at inducing protective immunity against H. pylori in mice," scientists in Melbourne, Australia report. "Immunisation with ISCOMATRIX (TM) and ISCOM (TM) vaccines resulted in a reduction in H. pylori colonisation equivalent to that induced by the gold standard cholera toxin (CT) adjuvant. Protection was induced in two mouse backgrounds, using two different bacterial antigens and following vaccine delivery via either the intranasal or subcutaneous route," wrote C.D....
Source: Vaccine Weekly (2008-09-03)
|
